Cargando…

Chemotherapy efficacy after first-line immunotherapy in 18 advanced melanoma patients

In BRAF wild type advanced melanoma, immune checkpoint blockers such as anti-PD1 (anti-programmed cell death 1) are usually continued beyond progression for a hypothetical rare further response. Chemotherapy as a second-line option is considered ineffective by many practitioners based on historical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saint-Jean, Mélanie, Fronteau, Clémentine, Peuvrel, Lucie, Khammari, Amir, Varey, Emilie, Quéreux, Gaëlle, Dréno, Brigitte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2020
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373626/ https://www.ncbi.nlm.nih.gov/pubmed/32702928 http://dx.doi.org/10.1097/MD.0000000000021329

Ejemplares similares

Visceral metastatic angiosarcoma treated effectively with oral cyclophosphamide combined with propranolol
por: Daguzé, Justine, et al.
Publicado: (2016)

Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy
por: Herbreteau, Guillaume, et al.
Publicado: (2018)

Tissue Biomarkers in Melanoma Patients Treated with TIL
por: Knol, Anne-Chantal, et al.
Publicado: (2012)

Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study
por: Herbreteau, Guillaume, et al.
Publicado: (2021)

Combination of alitretinoin and topical 5-fluorouracil in Darier disease
por: Soenen, Anouk, et al.
Publicado: (2018)

Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients
por: Saint-Jean, Mélanie, et al.
Publicado: (2018)

Dramatic response of an inoperable Merkel cell carcinoma with imatinib
por: Frenard, Cecile, et al.
Publicado: (2016)

Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients
por: Herbreteau, Guillaume, et al.
Publicado: (2020)

Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases
por: L’Orphelin, Jean-Matthieu, et al.
Publicado: (2021)

Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report
por: Quéreux, Gaelle, et al.
Publicado: (2017)

Proposal for an annual skin examination by a general practitioner for patients at high risk for melanoma: a French cohort study
por: Rat, Cédric, et al.
Publicado: (2015)

Anxiety, locus of control and sociodemographic factors associated with adherence to an annual clinical skin monitoring: a cross-sectional survey among 1000 high-risk French patients involved in a pilot-targeted screening programme for melanoma
por: Rat, Cédric, et al.
Publicado: (2017)

Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival
por: Khammari, Amir, et al.
Publicado: (2014)

Inclusion of populations at risk of advanced melanoma in an opportunistic targeted screening project involving general practitioners
por: Rat, Cédric, et al.
Publicado: (2016)

Influence de la crise sanitaire COVID-19 sur un éventuel retard au diagnostic dans le mélanome primitif
por: Stiot, Marie, et al.
Publicado: (2021)

A Bayesian network analysis of immunotherapy and taxane chemotherapy as second- or later-line treatments in non-small cell lung cancer
por: Liu, Xin-Xiu, et al.
Publicado: (2022)

The safety and efficacy of chemotherapy combined with immunotherapy for pancreatic cancer: A meta-analysis
por: Huang, Yang, et al.
Publicado: (2021)

Use of Smartphones for Early Detection of Melanoma: Systematic Review
por: Rat, Cédric, et al.
Publicado: (2018)

Successful chemotherapy with continuous immunotherapy for primary pulmonary endovascular epithelioid hemangioendothelioma: A case report
por: Guo, Wenliang, et al.
Publicado: (2023)

Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy
por: Kim, Se Hyun, et al.
Publicado: (2017)

Immunotherapy-related pneumonitis and bacterial pneumonia after the successful treatment of metastatic malignant melanoma with pembrolizumab: A case report
por: Ma, Qin, et al.
Publicado: (2021)

Third-line chemotherapy in advanced gastric cancer: A systematic review and meta-analysis
por: Zheng, Yu, et al.
Publicado: (2017)

A prognostic signature associated with cell senescence predicts survival outcomes and strongly associates with immunotherapy and chemotherapy response in breast cancer
por: Pan, Tao, et al.
Publicado: (2023)

Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis
por: Bai, Long, et al.
Publicado: (2016)

Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report
por: Fricke, Jeremy, et al.
Publicado: (2020)

Efficacy of cisplatin combined with vinorelbine as second- or higher-line palliative chemotherapy in patients with advanced ovarian cancer
por: Yeon, Sang Hoon, et al.
Publicado: (2023)

The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma
por: Zhao, Zheng, et al.
Publicado: (2023)

Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy
por: Lee, Myung-Won, et al.
Publicado: (2020)

Efficacy of first-line immunization combined with antiangiogenesis treatment and chemotherapy for the treatment of tongue cancer: A case report
por: Zhao, Limin, et al.
Publicado: (2023)

A Full GMP Process to Select and Amplify Epitope-Specific T Lymphocytes for Adoptive Immunotherapy of Metastatic Melanoma
por: Labarriere, N., et al.
Publicado: (2013)

Pemetrexed/cisplatin as first-line chemotherapy for advanced lung cancer with brain metastases: A case report and literature review
por: He, Guangzhao, et al.
Publicado: (2016)

Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report
por: Wang, Musen, et al.
Publicado: (2021)

Durable response to immunotherapy plus chemotherapy in a patient with untreated, brain-metastatic, EGFR exon 20 insertion mutation lung adenocarcinoma: A case report
por: Nong, Jingying, et al.
Publicado: (2021)

A case report of limbic encephalitis in a metastatic colon cancer patient during first-line bevacizumab-combined chemotherapy
por: Attademo, Laura, et al.
Publicado: (2018)

Usefulness of (18)F-Fluorodeoxyglucose Positron Emission Tomography for Follow-Up of 13-cis-Retinoic Acid Treatment for Residual Neuroblastoma After Myeloablative Chemotherapy
por: Sato, Yuya, et al.
Publicado: (2015)

Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG “GERMELATOX survey”) versus melanoma recurrence to quantify patients’ relative values for adjuvant therapy
por: Kaehler, Katharina C., et al.
Publicado: (2016)

Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials
por: Hao, Chunyan, et al.
Publicado: (2017)

Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review
por: Jing, Xu-Quan, et al.
Publicado: (2016)

Optimal induction chemotherapeutic regimen followed by concurrent chemotherapy plus intensity-modulated radiotherapy as first-line therapy for locoregionally advanced nasopharyngeal carcinoma
por: Wang, Fangzheng, et al.
Publicado: (2020)

The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy
por: Liu, Xiaofan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ppsmd4hf9fmp048s90tqg8li96